anti-CD19 CAR-T cells (Beijing Boren Hospital)

CAR-T cells targeting CD19 are an autologous or allogeneic cell therapy consisting of T cells genetically engineered to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19. CD19 is a transmembrane protein widely expressed on the surface of nearly all B-cell lineage cells, making it a primary target for treating B-cell malignancies. Upon binding to CD19-positive tumor cells, the CAR-T cells undergo activation, proliferation, and exert cytotoxic effects through the release of perforins and granzymes. In the context of Beijing Boren Hospital, these cells are often utilized in sequential therapy protocols alongside CAR-T cells targeting other antigens like CD22 or CD20 to overcome antigen escape and improve durable remission rates in patients with refractory or relapsed B-cell acute lymphoblastic leukemia (B-ALL).

Other names

CD19 CAR-TCD-19 CAR-TCD 19 CAR-TCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsanti-CD19 chimeric antigen receptor T-cellsanti-CD-19 chimeric antigen receptor T-cellsanti-CD 19 chimeric antigen receptor T-cellsCAR-T cells targeting CD19